AstraZeneca Sep 10, 2022 Lynparza Presents Possibility of Cure for Some Patients With Biomarker-Defined Ovarian Cancer Premium Sep 7, 2022 NICE Finds Lynparza Not Cost-Effective in BRCA1/2-Mutated Advanced Prostate Cancer Sep 6, 2022 UK's MHRA Approves Adjuvant Lynparza for BRCA-Mutant, High-Risk Early Breast Cancer Aug 26, 2022 Myriad Genetics Gets Expanded Coverage for BRACAnalysis CDx in Japan Aug 25, 2022 AstraZeneca's Tagrisso, Lynparza Net Adjuvant Approvals in Japan Aug 12, 2022 In Brief This Week: AstraZeneca, Merck, Stemline Therapeutics, Caris Life Sciences, Artios Pharma Aug 12, 2022 AstraZeneca, Daiichi Sankyo's Enhertu Scores FDA Accelerated Approval in HER2-Mutant Lung Cancer Aug 11, 2022 New Drugs Going After 'Achilles' Heel' Resistance Mutation in NSCLC Premium Aug 9, 2022 GSK, Mersana Therapeutics Ink $100M Option Agreement for Antibody-Drug Conjugate Aug 5, 2022 FDA Approves Enhertu for HER2-Low Metastatic Breast Cancer Aug 4, 2022 Merck, AstraZeneca Net European Approval for Adjuvant Lynparza in BRCA-Mutated Early Breast Cancer Jul 29, 2022 AstraZeneca Q2 Oncology Sales Grow 14 Percent as Firm Awaits Key Precision Drug Regulatory Decisions Premium Jul 19, 2022 Enhertu Racks Up Another EU Approval in Second-Line HER2-Positive Metastatic Breast Cancer Jul 18, 2022 Byondis, Medac File for European Approval of SYD985 for HER2-Positive Breast Cancer Jul 15, 2022 Almac, AstraZeneca CDx Partnership Branching Out to New Disease Areas, Drawing on NGS, qPCR Premium Jul 13, 2022 Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients Jul 7, 2022 Doctors, Payors, Lab Directors, Patients Have Distinct Views on What's Holding Up Precision Oncology Jun 27, 2022 EMA's CHMP Backs Approval for Enhertu, Lynparza for Two Breast Cancer Indications Jun 22, 2022 Daiichi Sankyo's Application for Enhertu in HER2-Low Breast Cancer to Commence European Review Jun 22, 2022 Biocartis, AstraZeneca Ink Companion Diagnostic Pact Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week: Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
